| Quarterly Financial Information [Table Text Block] |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Tc99m tilmanocept sales revenue
| | $ | 9 | | | $ | 4 | | | $ | 18 | | | $ | 9 | | Tc99m tilmanocept license revenue
| | | 254 | | | | 246 | | | | 1,296 | | | | — | | | Grant and other revenue | | | 686 | | | | 917 | | | | 511 | | | | 1,022 | | | Gross profit | | | 947 | | | | 1,166 | | | | 1,821 | | | | 975 | | | Operating expenses | | | 4,705 | | | | 3,407 | | | | 2,731 | | | | 4,215 | | | Loss from operations | | | (3,758 | ) | | | (2,241 | ) | | | (910 | ) | | | (3,240 | ) | | Loss from continuing operations | | | (2,682 | ) | | | (817 | ) | | | (1,761 | ) | | | (2,118 | ) | Gain (l oss) from discontinued operations, net of tax
| | | (1,004 | ) | | | (5,865 | ) | | | 1,702 | | | | (1,764 | ) | | Net loss attributable to common stockholders | | | (3,686 | ) | | | (6,681 | ) | | | (59 | ) | | | (3,882 | ) | Loss per common share (basic and diluted)
| | | | | | | | | | | | | | | | | | Continuing operations | | $ | (0.02 | ) | | $ | 0.00 | | | $ | (0.01 | ) | | $ | (0.01 | ) | | Discontinued operations | | $ | 0.00 | | | $ | (0.04 | ) | | $ | 0.01 | | | $ | (0.01 | ) | | Attributable to common stockholders | | $ | (0.02 | ) | | $ | (0.04 | ) | | $ | (0.00 | ) | | $ | (0.02 | ) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Tc99m tilmanocept sales revenue
| | $ | 4 | | | $ | — | | | $ | 9 | | | $ | 6 | | Tc99m tilmanocept license revenue
| | | 83 | | | | 250 | | | | 550 | | | | 250 | | | Grant and other revenue | | | 190 | | | | 654 | | | | 477 | | | | 540 | | | Gross profit | | | 276 | | | | 904 | | | | 1,034 | | | | 796 | | | Operating expenses | | | 6,900 | | | | 4,348 | | | | 5,947 | | | | 4,256 | | | Loss from operations | | | (6,623 | ) | | | (3,443 | ) | | | (4,912 | ) | | | (3,463 | ) | | Loss from continuing operations | | | (5,983 | ) | | | (8,171 | ) | | | (6,509 | ) | | | (1,946 | ) | | Loss from discontinued operations, net of tax | | | (1,309 | ) | | | (1,520 | ) | | | (1,562 | ) | | | (564 | ) | | Net loss attributable to common stockholders | | | (7,337 | ) | | | (9,691 | ) | | | (8,071 | ) | | | (2,510 | ) | Loss per common share (basic and diluted)
| | | | | | | | | | | | | | | | | | Continuing operations | | $ | (0.04 | ) | | $ | (0.05 | ) | | $ | (0.04 | ) | | $ | (0.02 | ) | | Discontinued operations | | $ | (0.01 | ) | | $ | (0.01 | ) | | $ | (0.01 | ) | | $ | 0.00 | | | Attributable to common stockholders | | $ | (0.05 | ) | | $ | (0.06 | ) | | $ | (0.05 | ) | | $ | (0.02 | ) | |